Mojtaba Gorji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mojtaba Gorji has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ali Asghar Kiani
Razi Herbal Medicines Research Center and School of Allied Medical Sciences, Department of Hematology and Blood Transfusion, Lorestan University of Medical Sciences, Khorramabad, Iran
1 shared publication - Ali Asghar Kiani
Department of Hematology and Blood Transfusion, Lorestan University, Khoramabad, Iran
1 shared publication Banafsheh Bahmani
Student Researcher, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
1 shared publicationFarhad Shahsavar
Department of Immunology, Lorestan University of Medical Sciences, School of Medicine, Khorramabad, Iran
1 shared publication- Kolsoum Ahmadi
Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
1 shared publication - Najmeh Ranji
Department of Biology, Ra.C., Islamic Azad University, Rasht, Iran
1 shared publication
Latest Publications
- 2 October 2017
- Published by Kamla Raj Enterprises in International Journal of Human Genetics
- Vol. 17 (4) , 145-150
New Mutations inAPCGene Among Familial Adenomatous Polyposis (FAP) Patients in Iran
Familial adenomatous polyposis (FAP) is a disorder by autosomal dominant inheritance caused by mutations in adenomatous polyposis coli (APC) gene. The aim of this paper was the investigation of a part of exon 15 of the APC gene in FAP patients in several provinces of Iran. Blood sample was obtained from FAP patients. A part of exon 15 of APC gene was amplified by PCR and underwent direct sequencing. Researchers found 23 FAP patients by severe polyposis in colorectal and identified new mutations in the three patients, including c.2910delT (17 year old) and c.3577-3578 delCA (30 and 34 year old) with severe polyposis and a substitution (N862K) in α patients. In this paper, small deletions in APC gene led to produce truncated non-functional APC protein. N862K mutation appears to be important for developing the disease. The results of this paper confirmed that there is a correlation between age of onset and phenotype with the proximity of the mutation to 5ʹ-end of gene.
- 2 October 2017
- Published by Kamla Raj Enterprises in International Journal of Human Genetics
- Vol. 17 (4) , 145-150
New Mutations inAPCGene Among Familial Adenomatous Polyposis (FAP) Patients in Iran
Familial adenomatous polyposis (FAP) is a disorder by autosomal dominant inheritance caused by mutations in adenomatous polyposis coli (APC) gene. The aim of this paper was the investigation of a part of exon 15 of the APC gene in FAP patients in several provinces of Iran. Blood sample was obtained from FAP patients. A part of exon 15 of APC gene was amplified by PCR and underwent direct sequencing. Researchers found 23 FAP patients by severe polyposis in colorectal and identified new mutations in the three patients, including c.2910delT (17 year old) and c.3577-3578 delCA (30 and 34 year old) with severe polyposis and a substitution (N862K) in α patients. In this paper, small deletions in APC gene led to produce truncated non-functional APC protein. N862K mutation appears to be important for developing the disease. The results of this paper confirmed that there is a correlation between age of onset and phenotype with the proximity of the mutation to 5ʹ-end of gene.
- Open Access
- 1 January 2016
- Published by Medknow in International Journal of Applied & Basic Medical Research
- Vol. 6 (4) , 271-275
Prevalence of Abelson murine leukemia viral oncogene homolog-breakpoint cluster region fusions and correlation with peripheral blood parameters in chronic myelogenous leukemia patients in Lorestan Province, Iran
Context: Chronic myelogenous leukemia (CML) is a chronic malignancy of myeloid linage associated with a significant increase in granulocytes in bone marrow and peripheral blood. CML diagnosis is based on detection of Philadelphia chromosome and “Abelson murine leukemia viral oncogene homolog” (ABL)-“breakpoint cluster region protein” fusions (ABL-BCR fusions). Aims: In this study, patients with CML morphology were studied according to ABL-BCR fusions and the relationship between the fusions and peripheral blood cell changes was examined. Materials and Methods: All patients suspected to chronic myeloproliferative disorders in Lorestan Province visiting subspecialist hematology clinics who were confirmed by oncologist were studied over a period of 5 years. After completing basic data questionnaire, blood samples were obtained with informed consent from the patients. Blood cell count and morphology were investigated and RNA was extracted from blood samples. cDNA was synthesized from RNA and ABL-BCR fusions including b3a2 and b2a2 (protein 210 kd or p210), e1a2 (protein 190 kdor p190), and e19a2 (protein 230 kdor p230) were studied by multiplex reverse transcription polymerase chain reaction method. Coexistence of e1a2 and b2a2 (p210/p190) fusions was also studied. The prevalence of mutations and their correlation with the blood parameters were statistically analyzed. Results: Of 58 patients positive for ABL-BCR fusion, 18 (30.5%) had b2a2 fusion, 37 (62.71%) had b3a2 fusion and three (3.08%) had e1a2 fusion. Coexistence of e1a2 and b2a2 (p210/p190) was not observed. There was no significant correlation between ABL-BCR fusions and white blood cell count, platelet count, and hemoglobin concentration. Conclusions: The ABL-BCR fusions in Lorestan Province were similar to other studies in Iran, and b3a2 fusion had the highest prevalence in the studied patients studied.
- 1 January 2016
- Published by Medknow in International Journal of Applied & Basic Medical Research
- Vol. 6 (4) , 271-275
Open AccessPrevalence of Abelson murine leukemia viral oncogene homolog-breakpoint cluster region fusions and correlation with peripheral blood parameters in chronic myelogenous leukemia patients in Lorestan Province, Iran
Context: Chronic myelogenous leukemia (CML) is a chronic malignancy of myeloid linage associated with a significant increase in granulocytes in bone marrow and peripheral blood. CML diagnosis is based on detection of Philadelphia chromosome and “Abelson murine leukemia viral oncogene homolog” (ABL)-“breakpoint cluster region protein” fusions (ABL-BCR fusions). Aims: In this study, patients with CML morphology were studied according to ABL-BCR fusions and the relationship between the fusions and peripheral blood cell changes was examined. Materials and Methods: All patients suspected to chronic myeloproliferative disorders in Lorestan Province visiting subspecialist hematology clinics who were confirmed by oncologist were studied over a period of 5 years. After completing basic data questionnaire, blood samples were obtained with informed consent from the patients. Blood cell count and morphology were investigated and RNA was extracted from blood samples. cDNA was synthesized from RNA and ABL-BCR fusions including b3a2 and b2a2 (protein 210 kd or p210), e1a2 (protein 190 kdor p190), and e19a2 (protein 230 kdor p230) were studied by multiplex reverse transcription polymerase chain reaction method. Coexistence of e1a2 and b2a2 (p210/p190) fusions was also studied. The prevalence of mutations and their correlation with the blood parameters were statistically analyzed. Results: Of 58 patients positive for ABL-BCR fusion, 18 (30.5%) had b2a2 fusion, 37 (62.71%) had b3a2 fusion and three (3.08%) had e1a2 fusion. Coexistence of e1a2 and b2a2 (p210/p190) was not observed. There was no significant correlation between ABL-BCR fusions and white blood cell count, platelet count, and hemoglobin concentration. Conclusions: The ABL-BCR fusions in Lorestan Province were similar to other studies in Iran, and b3a2 fusion had the highest prevalence in the studied patients studied.